Document is current

Any future updates will be listed below

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Crossref DOI link: https://doi.org/10.1007/s40273-016-0440-x

Published Online: 2016-08-09

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark